CO6180434A2 - Nuevas formas cristalinas de los compuestos ph(3-ci)(5-ochf2)-(r)ch(oh)c(o)-aze-pab(ome) (compuesto a) y ph(3-ci)(5-ochf2)-(r)ch(oh)c(o)-aze-pab(oh) (compuesto b) - Google Patents
Nuevas formas cristalinas de los compuestos ph(3-ci)(5-ochf2)-(r)ch(oh)c(o)-aze-pab(ome) (compuesto a) y ph(3-ci)(5-ochf2)-(r)ch(oh)c(o)-aze-pab(oh) (compuesto b)Info
- Publication number
- CO6180434A2 CO6180434A2 CO09057909A CO09057909A CO6180434A2 CO 6180434 A2 CO6180434 A2 CO 6180434A2 CO 09057909 A CO09057909 A CO 09057909A CO 09057909 A CO09057909 A CO 09057909A CO 6180434 A2 CO6180434 A2 CO 6180434A2
- Authority
- CO
- Colombia
- Prior art keywords
- aze
- ochf2
- pab
- compound
- ome
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Investigating Or Analyzing Materials Using Thermal Means (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
1.- Una forma cristalina de un compuesto seleccionado de Ph(3-Cl )(5-OCHF2)-(R)CH(OH)C(O)-.Aze-Pab(OMe) oPh(3-CI)(5-OCHF2)-(R)CH(OH)C(O)-Aze-Pab(OH).2.- Una forma sustancialmente cristalina de un compuesto seleccionado dePh(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-Aze-Pab(OMe) oPh(3-Cl )(5-OCHF2)-(R)CH(OH)C(O)-Aze-Pab(OH). 3.- Una forma cristalina de un compuesto como es reivindicado en la Reivindicación 1 ó 2 en forma de un anhidrato. 4.- El compuesto Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-Aze-Pab(OMe) anhidrato en forma cristalina como es reivindicado en cualquiera de las reivindicaciones 1 a 3, caracterizado por una curva de calorimetría diferencial de barrido, a una tasa de calentamiento 10°C/min en un vaso cerrado con orificios pequeños bajo flujo de nitrógeno, exhibiendo una endoterma con una temperatura de inicio extrapolada de alrededor de 109°C, una temperatura pico de alrededor de 115°C y/o un patrón de difracción de rayos X en polvo caracterizado por picos con valores-d a 15.2 Å. 10.8 Å, 6.8 Å. 6.0 Å. 5.2 Å. 4.79 Å. 4.23 Å y 3.98 Å. 5.- El compuesto en forma cristalina como es reivindicado en la Reivindicación 4 teniendo un patrón de difracción de rayos X en polvo caracterizado por picos con valores-d a 5.2 Å. 4.79 Å. 4.23 Å y 3.98 Å. 6.- El compuesto Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-Aze-Pab(OMe) anhidrato en forma cristalina como es reivindicado en la Reivindicación 1 que tiene un patrón de difracción de rayos X en polvo sustancialmente como es mostrado en la Figura 1. 7.- El compuesto Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-Aze-Pab(OH) anhidrato en forma cristalina como es reivindicado en cualquiera de las reivindicaciones 1 a 3, caracterizado por una curva de calorimetría diferencial de barrido, a una tasa de calentamiento de 10°C/min en un vaso cerrado con orificios pequeños bajo flujo de nitrógeno, exhibiendo una endoterma con una temperatura de inicio extrapolada de alrededor de 170°C y/o un patrón de difracción de rayos X en polvo caracterizado por picos con valores-d a 10.8 Å, 9.4 Å, 8.8 Å, 7.2 Å, 6.7 Å, 5.8 Å, 5.4 Å, 4.41 Å, 3.94 Å y 3.59 Å. 8.- El compuesto Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-Aze-Pab(OH) anhidrato en forma cristalina como es reivindicado en la Reivindicación 1 que tiene un patrón de difracción de rayos X en polvo sustancialmente como es mostrado en la Figura 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86875206P | 2006-12-06 | 2006-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6180434A2 true CO6180434A2 (es) | 2010-07-19 |
Family
ID=39232767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09057909A CO6180434A2 (es) | 2006-12-06 | 2009-06-04 | Nuevas formas cristalinas de los compuestos ph(3-ci)(5-ochf2)-(r)ch(oh)c(o)-aze-pab(ome) (compuesto a) y ph(3-ci)(5-ochf2)-(r)ch(oh)c(o)-aze-pab(oh) (compuesto b) |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7820645B2 (es) |
| EP (1) | EP2099750A1 (es) |
| JP (1) | JP2010511684A (es) |
| KR (1) | KR20090087107A (es) |
| CN (1) | CN101553466B (es) |
| AR (1) | AR064123A1 (es) |
| AU (1) | AU2007330605B2 (es) |
| BR (1) | BRPI0719908A2 (es) |
| CA (1) | CA2670678A1 (es) |
| CL (1) | CL2007003522A1 (es) |
| CO (1) | CO6180434A2 (es) |
| EC (1) | ECSP099389A (es) |
| IL (1) | IL198864A0 (es) |
| MX (1) | MX2009006036A (es) |
| MY (1) | MY147634A (es) |
| NO (1) | NO20091935L (es) |
| NZ (1) | NZ577240A (es) |
| PE (1) | PE20081445A1 (es) |
| RU (1) | RU2446156C2 (es) |
| SA (1) | SA07280675B1 (es) |
| TW (1) | TW200827336A (es) |
| UA (1) | UA97122C2 (es) |
| WO (1) | WO2008068475A1 (es) |
| ZA (1) | ZA200903614B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| AR034517A1 (es) | 2001-06-21 | 2004-02-25 | Astrazeneca Ab | Formulacion farmaceutica |
| SE0201661D0 (sv) * | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | New salts |
| US7781424B2 (en) * | 2003-05-27 | 2010-08-24 | Astrazeneca Ab | Modified release pharmaceutical formulation |
| TW200900033A (en) * | 2007-06-21 | 2009-01-01 | Wen-Qing Li | Automatic brewing machine |
| US20090061000A1 (en) * | 2007-08-31 | 2009-03-05 | Astrazeneca Ab | Pharmaceutical formulation use 030 |
| US9375678B2 (en) * | 2012-05-25 | 2016-06-28 | Georgia Tech Research Corporation | Metal-organic framework supported on porous polymer |
| US9994501B2 (en) | 2013-05-07 | 2018-06-12 | Georgia Tech Research Corporation | High efficiency, high performance metal-organic framework (MOF) membranes in hollow fibers and tubular modules |
| US9687791B2 (en) | 2013-05-07 | 2017-06-27 | Georgia Tech Research Corporation | Flow processing and characterization of metal-organic framework (MOF) membranes in hollow fiber and tubular modules |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU178398B (en) | 1979-06-12 | 1982-04-28 | Gyogyszerkutato Intezet | Process for producing new agmatine derivatives of activity against haemagglutination |
| JPS57149217A (en) | 1981-03-11 | 1982-09-14 | Kaken Pharmaceut Co Ltd | Slow-releasing pharmaceutical preparation |
| HU192646B (en) | 1984-12-21 | 1987-06-29 | Gyogyszerkutato Intezet | Process for preparing new n-alkyl-peptide aldehydes |
| IL77748A (en) | 1985-02-04 | 1991-11-21 | Merrell Dow Pharma | Amino acid and peptide derivatives as peptidase inhibitors |
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| US4792452A (en) | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
| EP0362002B1 (en) | 1988-09-01 | 1995-07-26 | Merrell Dow Pharmaceuticals Inc. | HIV protease inhibitors |
| ZA897515B (en) | 1988-10-07 | 1990-06-27 | Merrell Dow Pharma | Novel peptidase inhibitors |
| IT1229491B (it) | 1988-12-28 | 1991-09-03 | Roussel Maestretti S P A Ora R | Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali |
| TW201303B (es) | 1990-07-05 | 1993-03-01 | Hoffmann La Roche | |
| CA2075154A1 (en) | 1991-08-06 | 1993-02-07 | Neelakantan Balasubramanian | Peptide aldehydes as antithrombotic agents |
| SE9102462D0 (sv) | 1991-08-28 | 1991-08-28 | Astra Ab | New isosteric peptides |
| US5169638A (en) | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
| NZ245039A (en) | 1991-11-12 | 1994-12-22 | Lilly Co Eli | N-phenylalanyl and n-phenylglycyl derivatives of the dipeptide of l-azetidine-2-carboxylic acid and l-arginine aldehyde; anti-blood clotting compositions |
| SE9103612D0 (sv) | 1991-12-04 | 1991-12-04 | Astra Ab | New peptide derivatives |
| US5760235A (en) | 1992-03-04 | 1998-06-02 | Gyogyszerkutato Intezet Kft. | Anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for preparation thereof |
| TW223629B (es) | 1992-03-06 | 1994-05-11 | Hoffmann La Roche | |
| US5783563A (en) | 1993-06-03 | 1998-07-21 | Astra Aktiebolag | Method for treatment or prophylaxis of venous thrombosis |
| SE9301912D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | Process for the production of aminoalkylguandines |
| SE9301916D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
| US6984627B1 (en) | 1993-06-03 | 2006-01-10 | Astrazeneca Ab | Peptide derivatives |
| EP0648780A1 (en) | 1993-08-26 | 1995-04-19 | Bristol-Myers Squibb Company | Heterocyclic thrombin inhibitors |
| TW394760B (en) | 1993-09-07 | 2000-06-21 | Hoffmann La Roche | Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same |
| AU1025795A (en) | 1994-01-27 | 1995-08-03 | Mitsubishi Chemical Corporation | Prolineamide derivatives |
| US5707966A (en) | 1994-03-04 | 1998-01-13 | Eli Lilly And Company | Antithrombotic agents |
| IL112795A (en) | 1994-03-04 | 2001-01-28 | Astrazeneca Ab | Derivatives of peptides as antithrombotic drugs, their preparation, and pharmaceutical preparations containing them |
| US5705487A (en) | 1994-03-04 | 1998-01-06 | Eli Lilly And Company | Antithrombotic agents |
| US5561146A (en) | 1994-06-10 | 1996-10-01 | Bristol-Myers Squibb Company | Modified guanidino and amidino thrombin inhibitors |
| DE4421052A1 (de) | 1994-06-17 | 1995-12-21 | Basf Ag | Neue Thrombininhibitoren, ihre Herstellung und Verwendung |
| US5498724A (en) | 1994-06-28 | 1996-03-12 | Aktiebolaget Astra | Pyrazoleamidine compounds |
| US5510369A (en) | 1994-07-22 | 1996-04-23 | Merck & Co., Inc. | Pyrrolidine thrombin inhibitors |
| SI9620037A (sl) | 1995-02-17 | 1998-02-28 | Basf Aktiengesellschaft | Novi trombinski inhibitorji |
| US5710130A (en) | 1995-02-27 | 1998-01-20 | Eli Lilly And Company | Antithrombotic agents |
| US5695781A (en) | 1995-03-01 | 1997-12-09 | Hallmark Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers |
| US6083532A (en) | 1995-03-01 | 2000-07-04 | Duramed Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers and tablet formed therefrom |
| CA2216859A1 (en) | 1995-04-04 | 1996-10-10 | Merck & Co., Inc. | Thrombin inhibitors |
| US5629324A (en) | 1995-04-10 | 1997-05-13 | Merck & Co., Inc. | Thrombin inhibitors |
| SA96170106A (ar) | 1995-07-06 | 2005-12-03 | أسترا أكتيبولاج | مشتقات حامض أميني جديدة |
| TW541316B (en) | 1995-12-21 | 2003-07-11 | Astrazeneca Ab | Prodrugs of thrombin inhibitors |
| SE9601556D0 (sv) | 1996-04-24 | 1996-04-24 | Astra Ab | New pharmaceutical formulation of a thrombin inhibitor for parenteral use |
| SE9602263D0 (sv) | 1996-06-07 | 1996-06-07 | Astra Ab | New amino acid derivatives |
| JP2000514788A (ja) | 1996-06-25 | 2000-11-07 | イーライ・リリー・アンド・カンパニー | 抗凝固剤 |
| SE9602646D0 (sv) | 1996-07-04 | 1996-07-04 | Astra Ab | Pharmaceutically-useful compounds |
| DE19632772A1 (de) | 1996-08-14 | 1998-02-19 | Basf Ag | Neue Benzamidine |
| AR013084A1 (es) | 1997-06-19 | 2000-12-13 | Astrazeneca Ab | Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados |
| SE9704543D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Ab | New compounds |
| US6174913B1 (en) * | 1998-06-05 | 2001-01-16 | The University Of North Carolina At Chapel Hill | Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents |
| SE9802938D0 (sv) | 1998-09-01 | 1998-09-01 | Astra Ab | Improved stability for injection solutions |
| SE9802973D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| SE9802974D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | New crystalline forms |
| SE9804313D0 (sv) | 1998-12-14 | 1998-12-14 | Astra Ab | New compounds |
| US6599894B1 (en) | 1999-01-13 | 2003-07-29 | AstŕaZeneca AB | Amidinobenzylamine derivatives and their use as thrombin inhibitors |
| SE9902550D0 (sv) | 1999-07-02 | 1999-07-02 | Astra Ab | New crystalline forms |
| SE0001803D0 (sv) | 2000-05-16 | 2000-05-16 | Astrazeneca Ab | New compounds i |
| US6433186B1 (en) | 2000-08-16 | 2002-08-13 | Astrazeneca Ab | Amidino derivatives and their use as thormbin inhibitors |
| US7129233B2 (en) | 2000-12-01 | 2006-10-31 | Astrazeneca Ab | Mandelic acid derivatives and their use as thrombin inhibitors |
| AR035216A1 (es) | 2000-12-01 | 2004-05-05 | Astrazeneca Ab | Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios |
| SE0102921D0 (sv) | 2001-08-30 | 2001-08-30 | Astrazeneca Ab | Pharmaceutically useful compounds |
| US6287599B1 (en) | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| AR034517A1 (es) | 2001-06-21 | 2004-02-25 | Astrazeneca Ab | Formulacion farmaceutica |
| US6811794B2 (en) | 2001-12-20 | 2004-11-02 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
| SE0201659D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Modified release pharmaceutical formulation |
| SE0201661D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | New salts |
| SE0201658D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Immediate release pharmaceutical formulation |
| US7781424B2 (en) | 2003-05-27 | 2010-08-24 | Astrazeneca Ab | Modified release pharmaceutical formulation |
| SE0303220D0 (sv) | 2003-11-28 | 2003-11-28 | Astrazeneca Ab | New process |
| GB0503672D0 (en) | 2005-02-23 | 2005-03-30 | Astrazeneca Ab | New process |
| GB0510546D0 (en) | 2005-05-24 | 2005-06-29 | Astrazeneca Ab | New process |
-
2007
- 2007-12-03 TW TW096145953A patent/TW200827336A/zh unknown
- 2007-12-04 AR ARP070105412A patent/AR064123A1/es unknown
- 2007-12-05 US US11/950,568 patent/US7820645B2/en not_active Expired - Fee Related
- 2007-12-05 SA SA07280675A patent/SA07280675B1/ar unknown
- 2007-12-05 AU AU2007330605A patent/AU2007330605B2/en not_active Ceased
- 2007-12-05 EP EP07824793A patent/EP2099750A1/en not_active Withdrawn
- 2007-12-05 JP JP2009539800A patent/JP2010511684A/ja active Pending
- 2007-12-05 CN CN2007800452948A patent/CN101553466B/zh not_active Expired - Fee Related
- 2007-12-05 BR BRPI0719908-2A2A patent/BRPI0719908A2/pt not_active IP Right Cessation
- 2007-12-05 UA UAA200905000A patent/UA97122C2/ru unknown
- 2007-12-05 PE PE2007001717A patent/PE20081445A1/es not_active Application Discontinuation
- 2007-12-05 MY MYPI20092303A patent/MY147634A/en unknown
- 2007-12-05 MX MX2009006036A patent/MX2009006036A/es active IP Right Grant
- 2007-12-05 CL CL200703522A patent/CL2007003522A1/es unknown
- 2007-12-05 KR KR1020097013791A patent/KR20090087107A/ko not_active Application Discontinuation
- 2007-12-05 WO PCT/GB2007/004640 patent/WO2008068475A1/en active Application Filing
- 2007-12-05 RU RU2009119411/04A patent/RU2446156C2/ru not_active IP Right Cessation
- 2007-12-05 NZ NZ577240A patent/NZ577240A/en not_active IP Right Cessation
- 2007-12-05 CA CA002670678A patent/CA2670678A1/en not_active Abandoned
-
2009
- 2009-05-19 NO NO20091935A patent/NO20091935L/no not_active Application Discontinuation
- 2009-05-21 IL IL198864A patent/IL198864A0/en unknown
- 2009-05-25 ZA ZA200903614A patent/ZA200903614B/xx unknown
- 2009-06-04 CO CO09057909A patent/CO6180434A2/es not_active Application Discontinuation
- 2009-06-05 EC EC2009009389A patent/ECSP099389A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101553466A (zh) | 2009-10-07 |
| AU2007330605A1 (en) | 2008-06-12 |
| PE20081445A1 (es) | 2008-12-07 |
| ECSP099389A (es) | 2009-07-31 |
| RU2009119411A (ru) | 2011-01-20 |
| IL198864A0 (en) | 2010-02-17 |
| KR20090087107A (ko) | 2009-08-14 |
| CN101553466B (zh) | 2012-08-08 |
| CL2007003522A1 (es) | 2008-08-22 |
| SA07280675B1 (ar) | 2012-07-10 |
| ZA200903614B (en) | 2010-03-31 |
| CA2670678A1 (en) | 2008-06-12 |
| US7820645B2 (en) | 2010-10-26 |
| TW200827336A (en) | 2008-07-01 |
| AR064123A1 (es) | 2009-03-11 |
| MX2009006036A (es) | 2009-06-16 |
| NO20091935L (no) | 2009-07-03 |
| EP2099750A1 (en) | 2009-09-16 |
| MY147634A (en) | 2012-12-31 |
| JP2010511684A (ja) | 2010-04-15 |
| WO2008068475A1 (en) | 2008-06-12 |
| NZ577240A (en) | 2011-11-25 |
| UA97122C2 (ru) | 2012-01-10 |
| RU2446156C2 (ru) | 2012-03-27 |
| BRPI0719908A2 (pt) | 2014-03-04 |
| US20080287413A1 (en) | 2008-11-20 |
| AU2007330605B2 (en) | 2011-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6180434A2 (es) | Nuevas formas cristalinas de los compuestos ph(3-ci)(5-ochf2)-(r)ch(oh)c(o)-aze-pab(ome) (compuesto a) y ph(3-ci)(5-ochf2)-(r)ch(oh)c(o)-aze-pab(oh) (compuesto b) | |
| AR053748A1 (es) | Entidades quimicas, composiciones y metodos. | |
| BRPI0608886B8 (pt) | derivados de n-sulfonilpirróis e seus usos | |
| DOP2010000047A (es) | Compuestos de pirazol y su uso como inhibidores de raf | |
| UY31148A1 (es) | Compuestos de piperazina con accion herbicida (ii) | |
| MY153971A (en) | Sulfonamides as trpm8 modulators | |
| TW200745028A (en) | Novel sulphonylpyrroles | |
| EA201000269A1 (ru) | Новые гербициды | |
| ECSP10010195A (es) | Derivados de indolinona y procedimiento para su fabricación | |
| MY150583A (en) | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators | |
| UY31140A1 (es) | Compuestos de piperazina con accion herbicida | |
| EA201101060A1 (ru) | Новые гербициды | |
| EA201000272A1 (ru) | Трициклические мостиковые производные циклопентадиенона, как гербициды | |
| MX2011007998A (es) | Nuevos herbicidas. | |
| UA101590C2 (en) | Bazedoxifene salt | |
| MX2009004528A (es) | Nuevos derivados de fenilsulfamoilbenzamida como antagonistas de la bradiquinina. | |
| MX2011007932A (es) | Herbicidas nuevos. | |
| EA201101099A1 (ru) | Гербициды, полученные из циклопентадиона | |
| EA201100920A1 (ru) | Новые гербициды | |
| UY29668A1 (es) | Nuevos derivados de heptaazafenaleno, procedimientos para su obtencinn, ase como utilizacinn de estos como agentes protectores contra la radicacinn uv.- | |
| CO6290665A2 (es) | Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina | |
| EA201101097A1 (ru) | Новые микробиоциды | |
| MX2010002246A (es) | Nuevos herbicidas. | |
| ATE495225T1 (de) | Nach dem heissschmelzverfahren arbeitende tinte | |
| UY29390A1 (es) | Derivados nuevos de 3-aril-1,2-bencisoxazol, composiciones que los contienen y su utilización. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |